Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | LTA4H | P09960 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.41 |
| ▸ | TSHR | P16473 | 3/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | CD274 | Q9NZQ7 | 5/20 | 0.37 |
| ▸ | PDCD1 | Q15116 | 4/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | EP300 | Q09472 | 1/20 | 0.35 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6004092 | 0.88 | ALDH1A1 (0.44) | KDM4ELTA4HALDH1A1TSHRMAPK1 | |
| SCHEMBL6005596 | 0.82 | LTA4H (0.53) | KDM4ELTA4HALDH1A1MAPK1SMN1; SMN2 | |
| SCHEMBL22459108 | 0.77 | LTA4H (0.47) | KDM4ELTA4HALDH1A1TSHRMAPK1 | |
| SCHEMBL22458699 | 0.71 | LTA4H (0.47) | KDM4ELTA4HALDH1A1SMN1; SMN2 | |
| SCHEMBL24168885 | 0.70 | LTA4H (0.56) | LTA4HALDH1A1SMN1; SMN2FKBP1A | |
| SCHEMBL22459109 | 0.70 | LTA4H (0.56) | LTA4HALDH1A1SMN1; SMN2FKBP1A | |
| SCHEMBL22459103 | 0.70 | LTA4H (0.56) | LTA4HALDH1A1SMN1; SMN2FKBP1A | |
| SCHEMBL7181767 | 0.68 | MEN1 (0.60) | KDM4ELTA4HALDH1A1SMN1; SMN2FKBP1A | |
| SCHEMBL6540812 | 0.68 | MEN1 (0.60) | KDM4ELTA4HALDH1A1SMN1; SMN2FKBP1A | |
| SCHEMBL6006134 | 0.67 | TSHR (0.41) | KDM4EALDH1A1TSHRMAPK1RECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7019024-B2 | Pharmaceutical for treatment of neurological and neuropsychiatric disorders | ALLELIX NEUROSCIENCE INC. (US) | 2006-03-28 | — | — | US | disclosed |
| US-20010012857-A1 | Pharmaceutical for treatment of neurological and neuropsychiatric disorders | NPS PHARMACEUTICALS, INC. | 2001-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010012857-A1 | Pharmaceutical for treatment of neurological and neuropsychiatric disorders | SLC6A1, SLC18A2, SLC6A11 | KDM4E 2050/4885LTA4H 2230/4885ALDH1A1 357/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.